Skip to main content
. 2023 Dec 22;13(1):e6840. doi: 10.1002/cam4.6840

FIGURE 1.

FIGURE 1

Rates of HSR and desensitization to (A) platinum‐ and (B) taxane‐based chemotherapy in GC (epithelial ovarian/peritoneal/fallopian tube, endometrial, and cervical) and (C) to platinum‐ and (D) taxane‐based chemotherapy in ovarian cancer. HSR, hypersensitivity reaction; n, number of patients.